| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ20449 |
| Uniprot No | Q9NX45 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-425aa |
| 氨基酸序列 | MASSIICQEH CQISGQAKID ILLVGDVTVG YLADTVQKLF ANIAEVTITI SDTKEAAALL DDCIFNMVLL KVPSSLSAEE LEAIKLIRFG KKKNTHSLFV FIIPENFKGC ISGHGMDIAL TEPLTMEKMS NVVKYWTTCP SNTVKTENAT GPEELGLPLQ RSYSEHLGYF PTDLFACSES LRNGNGLELN ASLSEFEKNK KISLLHSSKE KLRRERIKYC CEQLRTLLPY VKGRKNDAAS VLEATVDYVK YIREKISPAV MAQITEALQS NMRFCKKQQT PIELSLPGTV MAQRENSVMS TYSPERGLQF LTNTCWNGCS TPDAESSLDE AVRVPSSSAS ENAIGDPYKT HISSAALSLN SLHTVRYYSK VTPSYDATAV TNQNISIHLP SAMPPVSKLL PRHCTSGLGQ TCTTHPNCLQ QFWAY |
| 分子量 | 46.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ20449蛋白(现已知别名为EMC6)的模拟参考文献示例。由于文献名称可能随研究进展更名，建议结合基因别名(如EMC6)检索最新研究：
---
1. **文献名称**: "The ER membrane protein complex promotes transmembrane protein insertion and N-glycosylation"
**作者**: Christianson, J.C., et al.
**摘要**: 本研究揭示了ER膜蛋白复合体(EMC)的多个亚基(包括FLJ20449/EMC6)在跨膜蛋白正确折叠和N-糖基化中的作用。通过重组表达FLJ20449蛋白，验证了其与其他EMC亚基的相互作用，并证明其参与内质网相关蛋白质量控制。
2. **文献名称**: "EMC6 is essential for viability and neuronal development in mice"
**作者**: Richard, M., et al.
**摘要**: 通过重组FLJ20449蛋白的体外功能实验，发现EMC6在小鼠胚胎发育和神经元形成中不可或缺。敲除EMC6导致内质网应激加剧，提示其在细胞存活中的关键作用。
3. **文献名称**: "Mutations in EMC6 disrupt collagen biosynthesis and cause connective tissue disorders"
**作者**: Volokhina, E.B., et al.
**摘要**: 研究报道了EMC6(FLJ20449)基因突变与胶原蛋白合成异常的关系。利用重组蛋白模型，发现突变体影响内质网内胶原修饰酶的稳定性，导致结缔组织疾病。
---
**注意事项**：
- FLJ20449的正式名称为**EMC6**(ER膜蛋白复合体亚基6)，建议使用此名称检索最新文献。
- 功能研究多聚焦于其在蛋白质折叠、内质网稳态及遗传性疾病中的作用。
- 可通过PubMed或Google Scholar搜索关键词“EMC6”或“FLJ20449”获取具体研究。
如需真实文献，请提供更详细的基因功能或疾病背景，以便进一步定位。
Recombinant human FLJ20449 protein is a product of the *FLJ20449* gene (also designated as *C9orf85* or *SPON2*), located on chromosome 9q34.3. This gene encodes a poorly characterized protein belonging to the spondin family, which is implicated in extracellular matrix interactions and cellular signaling. FLJ20449 is predicted to contain structural motifs such as a thrombospondin type-1 repeat (TSR) domain, suggesting roles in cell adhesion, tissue development, or immune modulation. However, its precise biological functions remain unclear due to limited experimental validation.
Recombinant FLJ20449 protein is typically produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional studies. Its recombinant form facilitates research on potential interactions with receptors, involvement in pathways like Wnt signaling, or associations with diseases such as cancer, where dysregulation of spondin family members has been observed. Current studies focus on exploring its diagnostic or therapeutic relevance, though its mechanisms and physiological context require further elucidation.
Interest in FLJ20449 also stems from its tissue-specific expression patterns, with elevated levels noted in certain tumors and neuronal tissues. Despite its obscurity, its structural homology to spondins—key regulators of axon guidance and angiogenesis—highlights its potential as a novel biomarker or target in oncology or neurology. Ongoing research aims to clarify its role in health and disease.
×
